Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

Detalles Bibliográficos
Autores principales: Camelo, Ricardo Mesquita, de Medeiros, Tenille Capuxú, de Albuquerque, Daniela Gonçalves Braz, Álvares-Teodoro, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938495/
https://www.ncbi.nlm.nih.gov/pubmed/34303653
http://dx.doi.org/10.1016/j.htct.2021.02.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938495/
https://www.ncbi.nlm.nih.gov/pubmed/34303653
http://dx.doi.org/10.1016/j.htct.2021.02.010

Ejemplares similares